Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05620407




Registration number
NCT05620407
Ethics application status
Date submitted
10/11/2022
Date registered
17/11/2022
Date last updated
14/06/2024

Titles & IDs
Public title
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2)
Secondary ID [1] 0 0
2022-500700-22
Secondary ID [2] 0 0
IM011-247
Universal Trial Number (UTN)
Trial acronym
POETYK SLE-2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Systemic Lupus Erythematosus 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Deucravacitinib
Other interventions - Placebo

Experimental: Arm 1: Deucravacitinib -

Placebo comparator: Arm 2: Placebo -


Treatment: Drugs: Deucravacitinib
Specified dose on specified days

Other interventions: Placebo
Specified dose on specified days
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of participants who achieve Systemic Lupus Erythematosus Responder Index-4 [SRI(4)] response
Timepoint [1] 0 0
At week 52
Secondary outcome [1] 0 0
Proportion of participants who achieve British Isles Lupus Assessment Group-based Combined Lupus Assessment (BICLA) response
Timepoint [1] 0 0
At week 52
Secondary outcome [2] 0 0
Proportion of participants who achieve both SRI(4) and BICLA (dual responders)
Timepoint [2] 0 0
At week 52
Secondary outcome [3] 0 0
Proportion of participants with a Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score = 10 at baseline who achieve a CLASI response, defined as a decrease of = 50% from baseline CLASI activity score
Timepoint [3] 0 0
At week 52
Secondary outcome [4] 0 0
Proportion of participants who achieve Lupus Low Disease Activity State (LLDAS)
Timepoint [4] 0 0
At week 52
Secondary outcome [5] 0 0
Proportion of participants taking = 7.5 mg/day prednisone (or equivalent) at Week 24 with no dose increase beyond protocol-specified limits
Timepoint [5] 0 0
Up to 52 weeks
Secondary outcome [6] 0 0
Proportion of participants with = 6 active (tender + swollen) joints at baseline who achieve at least 50% from baseline reduction in active (tender + swollen) joints
Timepoint [6] 0 0
At week 52
Secondary outcome [7] 0 0
Change from baseline in patient-reported fatigue according to Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue
Timepoint [7] 0 0
At week 52
Secondary outcome [8] 0 0
Number of participants with adverse events (AEs)
Timepoint [8] 0 0
Up to 156 weeks
Secondary outcome [9] 0 0
Number of participants with serious adverse events (SAEs)
Timepoint [9] 0 0
Up to 156 weeks
Secondary outcome [10] 0 0
Number of participants with AEs leading to discontinuation of treatment
Timepoint [10] 0 0
Up to 156 weeks
Secondary outcome [11] 0 0
Number of participants with AEs leading to study discontinuation
Timepoint [11] 0 0
Up to 156 weeks
Secondary outcome [12] 0 0
Number of participants with target adverse events of special interest (AESIs)
Timepoint [12] 0 0
Up to 156 weeks
Secondary outcome [13] 0 0
Number of participants with laboratory abnormalities
Timepoint [13] 0 0
Up to 156 weeks
Secondary outcome [14] 0 0
Number of participants with electrocardiogram (ECG) abnormalities
Timepoint [14] 0 0
Up to 156 weeks
Secondary outcome [15] 0 0
Number of participants with vital sign abnormalities
Timepoint [15] 0 0
Up to 156 weeks

Eligibility
Key inclusion criteria
Inclusion Criteria

* Diagnosed with Systemic Lupus Erythematosus (SLE) at least 24 weeks before the screening visit.
* Meet the European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) 2019 classification criteria for SLE.
* One of the following: positive antinuclear antibodies (ANA) = 1:80 at screening OR positive anti dsDNA OR positive anti Smith (anti Sm) as determined by the central laboratory at screening.
* Total Systemic Lupus Erythematosus Disease Activity Index-2K (SLEDAI-2K) score = 6 points and clinical SLEDAI 2K score = 4 points with joint involvement, and/or cutaneous vasculitis, and/or rash.
* Lupus headache, alopecia, organic brain syndrome, and mucosal ulcers must be recorded on SLEDAI 2K, if indicated, but do not count toward the points required for screening at entry.
* At least one SLE background therapy(immunosuppressant and/or antimalarial) is required for = 12 weeks before the screening visit, must be at a stable dose for = 8 weeks before the screening visit, and must remain stable until randomization and throughout study participation.
* Oral corticosteroid (OCS; prednisone or equivalent) background therapy is permitted but not required. For participants taking OCS, the dose must be stable for = 2 weeks before the screening visit, cannot exceed 30 mg/day at screening, and must remain stable until the Week 4 visit. Participants can be on an OCS as well as an antimalarial and/or an immunosuppressant.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

* Diagnosis of drug-induced SLE rather than idiopathic SLE.
* Other autoimmune diseases (eg, multiple sclerosis, psoriasis, inflammatory bowel disease, etc.) are excluded. Participants with type I autoimmune diabetes mellitus, thyroid autoimmune disease, Celiac disease, or secondary Sjögren's syndrome are not excluded -SLE overlap syndromes including, but not limited to, rheumatoid arthritis, scleroderma, and mixed connective tissue disease are excluded.
* Active or unstable lupus neuropsychiatric manifestations, including, but not limited to, any condition defined by BILAG A criteria.
* Active, severe Class III, and IV, lupus nephritis that requires or may require treatment with cytotoxic agents or high-dose CS.
* History of congenital or acquired immunodeficiency.
* Known active infection, or any major episode of infection requiring hospitalization or treatment with parenteral (intramuscular or IV) antimicrobial agents (eg, antibiotics antiviral, antifungal, or antiparasitic agents) within 30 days of randomization, or treatment with oral antimicrobial agents within 2 weeks of randomization -Currently on any therapy for chronic infection (eg, pneumocystis, herpes zoster, cytomegalovirus, invasive bacterial or fungal infections, or atypical mycobacteria).
* Taking more than 1 immunosuppressant at screening.
* In Japan only: Participants with positive result of ß - D-glucan assay.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/01/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
17/12/2027
Actual
Sample size
Target
490
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [2] 0 0
BJC Health - Paramatta
Recruitment hospital [3] 0 0
Rheumatology Research Unit - Maroochydore
Recruitment hospital [4] 0 0
Austin Health - Repatriation Hospital - Ivanhoe
Recruitment hospital [5] 0 0
RK Will Pty Ltd - Victoria Park
Recruitment postcode(s) [1] 0 0
2170 - Liverpool
Recruitment postcode(s) [2] 0 0
2150 - Paramatta
Recruitment postcode(s) [3] 0 0
4558 - Maroochydore
Recruitment postcode(s) [4] 0 0
3079 - Ivanhoe
Recruitment postcode(s) [5] 0 0
6100 - Victoria Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
Nevada
Country [9] 0 0
United States of America
State/province [9] 0 0
New Jersey
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Oklahoma
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
Argentina
State/province [19] 0 0
Buenos Aires
Country [20] 0 0
Argentina
State/province [20] 0 0
Ciudad Autónoma De Buenos Aires
Country [21] 0 0
Argentina
State/province [21] 0 0
Tucumán
Country [22] 0 0
Argentina
State/province [22] 0 0
Río Cuarto
Country [23] 0 0
Brazil
State/province [23] 0 0
Espírito Santo
Country [24] 0 0
Brazil
State/province [24] 0 0
Rio Grande Do Sul
Country [25] 0 0
Brazil
State/province [25] 0 0
São Paulo
Country [26] 0 0
Brazil
State/province [26] 0 0
Curitiba
Country [27] 0 0
Brazil
State/province [27] 0 0
Rio de Janeiro
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Plovdiv
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Ruse
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Sofia
Country [31] 0 0
Chile
State/province [31] 0 0
Coquimbo
Country [32] 0 0
Chile
State/province [32] 0 0
Los Ríos
Country [33] 0 0
Chile
State/province [33] 0 0
Región Metropolitana De Santiago
Country [34] 0 0
Chile
State/province [34] 0 0
Santiago
Country [35] 0 0
Czechia
State/province [35] 0 0
Ostrava Mesto
Country [36] 0 0
Czechia
State/province [36] 0 0
Praha 2
Country [37] 0 0
Greece
State/province [37] 0 0
Attikí (Region)
Country [38] 0 0
Greece
State/province [38] 0 0
Attikí
Country [39] 0 0
Greece
State/province [39] 0 0
Thessalía
Country [40] 0 0
Hungary
State/province [40] 0 0
Baranya
Country [41] 0 0
Hungary
State/province [41] 0 0
Békés
Country [42] 0 0
Hungary
State/province [42] 0 0
Csongrád
Country [43] 0 0
Hungary
State/province [43] 0 0
Veszprém City
Country [44] 0 0
India
State/province [44] 0 0
Delhi
Country [45] 0 0
India
State/province [45] 0 0
Gujarat
Country [46] 0 0
India
State/province [46] 0 0
Karnataka
Country [47] 0 0
India
State/province [47] 0 0
Tamil Nadu
Country [48] 0 0
India
State/province [48] 0 0
Telangana
Country [49] 0 0
Japan
State/province [49] 0 0
Aichi
Country [50] 0 0
Japan
State/province [50] 0 0
Fukui
Country [51] 0 0
Japan
State/province [51] 0 0
Fukuoka
Country [52] 0 0
Japan
State/province [52] 0 0
Hokkaido
Country [53] 0 0
Japan
State/province [53] 0 0
Kagawa
Country [54] 0 0
Japan
State/province [54] 0 0
Kanagawa
Country [55] 0 0
Japan
State/province [55] 0 0
Miyagi
Country [56] 0 0
Japan
State/province [56] 0 0
Nagasaki
Country [57] 0 0
Japan
State/province [57] 0 0
Saitama
Country [58] 0 0
Japan
State/province [58] 0 0
Tochigi
Country [59] 0 0
Japan
State/province [59] 0 0
Tokyo
Country [60] 0 0
Japan
State/province [60] 0 0
Chiba
Country [61] 0 0
Japan
State/province [61] 0 0
Fukushima
Country [62] 0 0
Japan
State/province [62] 0 0
Gifu
Country [63] 0 0
Japan
State/province [63] 0 0
Niigata
Country [64] 0 0
Japan
State/province [64] 0 0
Okayama
Country [65] 0 0
Japan
State/province [65] 0 0
Osaka
Country [66] 0 0
Japan
State/province [66] 0 0
Wakayama
Country [67] 0 0
Mexico
State/province [67] 0 0
Coahuila
Country [68] 0 0
Mexico
State/province [68] 0 0
Distrito Federal
Country [69] 0 0
Mexico
State/province [69] 0 0
Guanajuato
Country [70] 0 0
Mexico
State/province [70] 0 0
Jalisco
Country [71] 0 0
Mexico
State/province [71] 0 0
Morelos
Country [72] 0 0
Mexico
State/province [72] 0 0
Nuevo LEON
Country [73] 0 0
Mexico
State/province [73] 0 0
Chihuahua
Country [74] 0 0
Mexico
State/province [74] 0 0
Oaxaca
Country [75] 0 0
Peru
State/province [75] 0 0
Lima
Country [76] 0 0
Poland
State/province [76] 0 0
Lubelskie
Country [77] 0 0
Poland
State/province [77] 0 0
Mazowieckie
Country [78] 0 0
Poland
State/province [78] 0 0
Malopolskie
Country [79] 0 0
Poland
State/province [79] 0 0
Warminsko-mazurskie
Country [80] 0 0
Poland
State/province [80] 0 0
Wielkopolskie
Country [81] 0 0
Poland
State/province [81] 0 0
Szczecin
Country [82] 0 0
Poland
State/province [82] 0 0
Warszawa
Country [83] 0 0
Poland
State/province [83] 0 0
Wroclaw
Country [84] 0 0
Poland
State/province [84] 0 0
Lódzkie
Country [85] 0 0
Portugal
State/province [85] 0 0
Lisboa
Country [86] 0 0
Portugal
State/province [86] 0 0
Bila Nova De Gaia
Country [87] 0 0
Portugal
State/province [87] 0 0
Lisbon
Country [88] 0 0
Puerto Rico
State/province [88] 0 0
San Juan
Country [89] 0 0
Singapore
State/province [89] 0 0
Singapore
Country [90] 0 0
Spain
State/province [90] 0 0
Badajoz
Country [91] 0 0
Spain
State/province [91] 0 0
Barcelona [Barcelona]
Country [92] 0 0
Spain
State/province [92] 0 0
Cantabria
Country [93] 0 0
Spain
State/province [93] 0 0
Madrid
Country [94] 0 0
Spain
State/province [94] 0 0
País Vasco
Country [95] 0 0
Spain
State/province [95] 0 0
Sevilla
Country [96] 0 0
Spain
State/province [96] 0 0
Valladolid
Country [97] 0 0
Spain
State/province [97] 0 0
València
Country [98] 0 0
Taiwan
State/province [98] 0 0
Kaohsiung
Country [99] 0 0
Taiwan
State/province [99] 0 0
Taichung
Country [100] 0 0
Taiwan
State/province [100] 0 0
Tainan City
Country [101] 0 0
Taiwan
State/province [101] 0 0
Taipei
Country [102] 0 0
Thailand
State/province [102] 0 0
Krung Thep Maha Nakhon
Country [103] 0 0
Turkey
State/province [103] 0 0
Ankara
Country [104] 0 0
Turkey
State/province [104] 0 0
Antalya
Country [105] 0 0
Turkey
State/province [105] 0 0
Gaziantep
Country [106] 0 0
Turkey
State/province [106] 0 0
Istanbul
Country [107] 0 0
United Kingdom
State/province [107] 0 0
Greater London
Country [108] 0 0
United Kingdom
State/province [108] 0 0
London, City Of
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Middlesbrough
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Bradford
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Trial website
https://clinicaltrials.gov/study/NCT05620407
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Address 0 0
Country 0 0
Phone 0 0
855-907-3286
Fax 0 0
Email 0 0
Clinical.Trials@bms.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05620407